Roche to use Exscientia’s Centaur Chemist to identify preclinical candidates
Executive Summary
Exscientia Ltd. agreed to use its artificial intelligence (AI) drug discovery platform Centaur Chemist to discover preclinical candidates for Roche, which will have exclusive development and marketing rights.
Deal Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice